
Cross-disease transcriptomic meta-analysis and network pharmacology reveal key therapeutic targets in rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPOGtTRE9HZHRCQS1LQTdGVU1uTEwtd3VCODI2Y19KdEg4TDlwSURhNnhRckhvMEIxZGZMWTdOdWZEV1NCYWxLWWRRa1dyUXBqSWp2Z0dKYXBicnBBU0FEUThXSTRxWGs0VXNZUW5UZ1dSRGFpeXFGWFBlM1NGNzhnVE5tbHo3cmNVa2EwS0wxSW1sQkJMemFj?oc=5" target="_blank">Cross-disease transcriptomic meta-analysis and network pharmacology reveal key therapeutic targets in rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis</a>&nbsp;&nbsp;<font color="#6f6f6f">Frontiers</font>

